Mr. Ron Nagar reports

TEMPRAMED SIGNS LETTER OF INTENT WITH CPO GREECE FOR EXCLUSIVE DISTRIBUTION OF VIVI PRODUCTS IN GREECE

Tempramed Technologies Ltd. has signed a non-binding letter of intent (the LOI) dated July 30, 2026, with CPO Greece (CPO) regarding the proposed exclusive distribution of VIVI Cap and VIVI Epi in Greece.

Highlights:

• LOI with CPO Greece includes exclusive distribution of VIVI Cap and VIVI Epi throughout Greece, subject to a definitive agreement.
• Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20 per cent year over year to maintain exclusivity.
• Transfer pricing and the first-year minimum unit commitment will be negotiated and established in the definitive distribution agreement.
• CPO Greece brings an established pharmacy division, local distribution infrastructure and experience representing international health care and consumer brands.
• Adding and renewing agreements in markets outside the United States since Q4 2025 including: Panama, Mexico, South Korea, Turkey, Saudi Arabia, Israel, Kuwait, Brazil, Europe (Benelux) and Greece.

Under the LOI, Tempramed proposes to appoint CPO as the exclusive distributor of VIVI Cap and VIVI Epi in Greece, subject to the execution of a definitive distribution agreement and CPO's compliance with minimum purchase obligations. The specific transfer prices and first-year minimum unit commitment have not yet been finalized and are to be established in the definitive agreement.

To maintain the proposed exclusivity, CPO would be required to increase its total annual combined purchases of VIVI Cap and VIVI Epi by no less than 20 per cent year over year. CPO Greece is part of CPO Group, an established importer, distributor and exclusive agent serving the health, beauty, personal-care and food sectors. Founded in 1928, the group represents a broad portfolio that includes pharmaceutical products, as well as hospital, medical, analytical and dental supplies. Tempramed believes CPO's pharmacy-market experience, local commercial relationships and distribution capabilities make it a strong prospective partner for the company's entry into Greece.

The proposed relationship supports Tempramed's strategy of expanding through experienced local partners that can navigate country-specific pharmacy channels and build sustained product adoption. If a definitive agreement is completed, Greece would become an additional European market for two of Tempramed's commercial medication-protection products.

"CPO Greece is exactly the kind of established, market-facing partner we want as we expand Tempramed's global commercial footprint," said Ron Nagar, founder and chief executive officer of Tempramed. "Its deep pharmacy-market experience and local distribution capabilities provide a strong foundation for introducing VIVI Cap and VIVI Epi across Greece. The proposed 20-per-cent annual purchase-growth requirement reflects our intention to build this relationship for scale, not simply market entry. We are focused on converting this LOI into a definitive agreement and, subject to completing that agreement and satisfying all applicable requirements, establishing Greece as a meaningful European market for Tempramed. This LOI reinforces our confidence in the global relevance of our passive, battery-free technology and its ability to address an important everyday need for patients using temperature-sensitive medications."

About CPO Greece

CPO Greece is part of CPO Group, a leading importer, distributor and exclusive agent for high-quality products across the health, beauty, personal care and food sectors. Founded in 1928, CPO Group has built a broad portfolio spanning mass-market goods, premium cosmetics, pharmaceutical products and hospital, medical, analytical, and dental supplies. CPO Greece operates dedicated pharmacy, medical, consumer and export divisions, and supports international brands through local market development, sales, distribution and logistics.

About Tempramed Technologies Ltd.

Tempramed Technologies is a global medical-device company with a portfolio of innovative, temperature-controlled medication-storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, Food and Drug Administration-registered thermal-insulation devices that operate continuously without batteries or external power. Its commercial product portfolio includes VIVI Cap, VIVI Cap Smart, VIVI Epi and VIVI Med. Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, anytime.

We seek Safe Harbor.